Skip to main content
. 2018 Apr 12;11:494–507. doi: 10.1016/j.omtn.2018.04.001

Figure 4.

Figure 4

miR372 Enhances Phosphorylation of YB-1 in Liver Cancer Cells

(A) RT-PCR analysis with HULC primers and western blotting with anti-PTEN in liver cancer cells Hep3B cell lines infected with rLV and rLV-miR372 and treated with miR372 inhibitor, respectively. β-actin as internal control is shown. (B) RNA immunoprecipitation (RIP) anti-CTCF followed by RT-PCR with HULC primers in liver cancer cells Hep3B cell lines infected with rLV and rLV-miR372, respectively, is shown. IgG RIP as negative control is shown. HULC as INPUT is shown. (C) RIP anti-YB-1, anti-ERK1/2, and anti-PTEN followed by RT-PCR with HULC primers in liver cancer cells Hep3B cell lines infected with rLV and rLV-miR372, respectively, are shown. IgG RIP as negative control is shown. HULC as INPUT is shown. (D) Co-immunoprecipitation (coIP) with anti-ERK1 followed by western blotting with anti-YB-1 and anti-PTEN in the Hep3B cell lines infected with rLV and rLV-miR372, respectively, is shown. IgG IP as negative control is shown. INPUT refers to western blotting with anti-YB-1 and anti-ERK1/2. (E) Western blotting analysis with anti-pYB1 in liver cancer cells Hep3B cell lines infected with rLV, rLV-miR372, and rLV-miR372 plus pGFP-V-RS-HULC, respectively, is shown. β-actin as internal control is shown.